Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Kyntra Bio (KYNB) over the last 11 years, with Q3 2025 value amounting to $12000.0.

  • Kyntra Bio's Gains from Investment Securities fell 8918.92% to $12000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $75000.0, marking a year-over-year decrease of 8700.17%. This contributed to the annual value of $5.8 million for FY2024, which is 191.7% up from last year.
  • As of Q3 2025, Kyntra Bio's Gains from Investment Securities stood at $12000.0, which was down 8918.92% from $12000.0 recorded in Q2 2025.
  • Kyntra Bio's 5-year Gains from Investment Securities high stood at $4.8 million for Q1 2021, and its period low was $12000.0 during Q2 2025.
  • Moreover, its 5-year median value for Gains from Investment Securities was $312000.0 (2022), whereas its average is $824437.5.
  • Per our database at Business Quant, Kyntra Bio's Gains from Investment Securities surged by 4900.74% in 2022 and then tumbled by 9409.28% in 2024.
  • Quarter analysis of 5 years shows Kyntra Bio's Gains from Investment Securities stood at $638000.0 in 2021, then fell by 5.17% to $605000.0 in 2022, then crashed by 60.83% to $237000.0 in 2023, then crashed by 94.09% to $14000.0 in 2024, then decreased by 14.29% to $12000.0 in 2025.
  • Its last three reported values are $12000.0 in Q3 2025, $12000.0 for Q2 2025, and $37000.0 during Q1 2025.